AR050102A1 - Polipeptidos de fusion de vih para la prevencion y /o tratamiento del sida - Google Patents

Polipeptidos de fusion de vih para la prevencion y /o tratamiento del sida

Info

Publication number
AR050102A1
AR050102A1 ARP050103260A ARP050103260A AR050102A1 AR 050102 A1 AR050102 A1 AR 050102A1 AR P050103260 A ARP050103260 A AR P050103260A AR P050103260 A ARP050103260 A AR P050103260A AR 050102 A1 AR050102 A1 AR 050102A1
Authority
AR
Argentina
Prior art keywords
polypeptide
composition
gag
previous
immunogenic
Prior art date
Application number
ARP050103260A
Other languages
English (en)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of AR050102A1 publication Critical patent/AR050102A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se refiere a nuevas fusiones de polipéptidos y polinucleotidos de VIH de Gal, Pol y Nef que son utiles en composiciones inmunogénicas y vacunas. La invencion se refiere en particular a un polipéptido que comprende Nef o un fragmento inmunogénico de la misma, y p17 Gag y/o p24 Gag o fragmentos inmunogénicos de las mismas, en el que cuando ambas p17 y p24 Gag están presentes hay al menos un antígeno de VIH o fragmento inmunogénico entre ellos. El polipéptido también puede comprender Pol o RT o un fragmento inmunogénico de las mismas. Reivindicacion 8: Un procedimiento para la purificacion de un polipéptido de acuerdo con algunas de las reivindicaciones 1 a 7, tal procedimiento comprende: i) proporcionar una composicion que comprende el polipéptido no purificado; ii) someter la composicion a al menos dos etapas cromatográficas; iii) de forma opcionan carboxiamidacion del polipéptido; v) llevar a cabo una etapa de intercambio en tampon para proporcionar la proteína en un tampon adecuado para una formulacion farmacéutica. Reivindicacion 27: Una composicion farmacéutica que comprende un polipéptido o polinucleotido o composicion de polipéptidos o polinucleotidos de acuerdo con cualquier reivindicacion previa o un polipéptido purificado de acuerdo con cualquier reivindicacion previa, o un polipéptido purificado de acuerdo con cualquier reivindicacion previa, junto con un vehículo o adyuvante farmacéuticamente aceptable.
ARP050103260A 2004-08-05 2005-08-04 Polipeptidos de fusion de vih para la prevencion y /o tratamiento del sida AR050102A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0417494.2A GB0417494D0 (en) 2004-08-05 2004-08-05 Vaccine

Publications (1)

Publication Number Publication Date
AR050102A1 true AR050102A1 (es) 2006-09-27

Family

ID=32982606

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050103260A AR050102A1 (es) 2004-08-05 2005-08-04 Polipeptidos de fusion de vih para la prevencion y /o tratamiento del sida
ARP110100503A AR080216A2 (es) 2004-08-05 2011-02-18 Composiciones farmaceuticas que contienen una proteina de fusion de vih

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP110100503A AR080216A2 (es) 2004-08-05 2011-02-18 Composiciones farmaceuticas que contienen una proteina de fusion de vih

Country Status (31)

Country Link
US (2) US7612173B2 (es)
EP (3) EP1773999B1 (es)
JP (3) JP2008507987A (es)
KR (1) KR101501495B1 (es)
CN (2) CN101035897B (es)
AR (2) AR050102A1 (es)
AT (1) ATE443769T1 (es)
AU (1) AU2005268856B2 (es)
BR (1) BRPI0514108A (es)
CA (1) CA2575898C (es)
CY (1) CY1109667T1 (es)
DE (1) DE602005016810D1 (es)
DK (1) DK1773999T3 (es)
ES (3) ES2334044T3 (es)
GB (1) GB0417494D0 (es)
HR (1) HRP20090678T1 (es)
IL (2) IL180947A0 (es)
MA (1) MA28983B1 (es)
MX (1) MX2007001515A (es)
MY (1) MY145614A (es)
NO (1) NO20070988L (es)
NZ (1) NZ552976A (es)
PE (1) PE20060577A1 (es)
PL (1) PL1773999T3 (es)
PT (1) PT1773999E (es)
RU (1) RU2441878C2 (es)
SG (1) SG155206A1 (es)
SI (1) SI1773999T1 (es)
TW (1) TWI365191B (es)
WO (1) WO2006013106A2 (es)
ZA (1) ZA200700771B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
EP1039880A1 (en) * 1998-10-23 2000-10-04 Idea Innovative Dermale Applikationen GmbH Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates
PT1031347E (pt) 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
SI1031346T1 (en) 1999-01-27 2002-08-31 Idea Ag Noninvasive vaccination through the skin
AU5409699A (en) * 1999-07-05 2001-01-22 Idea Ag A method for the improvement of transport across adaptable semi-permeable barriers
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
EP1811961A2 (en) * 2004-11-12 2007-08-01 Idea Ag Extended surface aggregates in the treatment of skin conditions
AU2006245920A1 (en) * 2005-05-12 2006-11-16 Glaxo Group Limited Vaccine composition
WO2006130855A2 (en) 2005-06-01 2006-12-07 California Institute Of Technology Method of targeted gene delivery using viral vectors
CA2651764A1 (en) * 2006-05-09 2007-11-22 Gerald V. Quinnan Hiv-1 immunogenic compositions
PL2048955T3 (pl) 2006-07-21 2013-11-29 California Inst Of Techn Nakierowane dostarczanie genu dla szczepienia komórek dendrytycznych
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
MX2009009342A (es) 2007-03-02 2009-09-11 Glaxosmithkline Biolog Sa Metodo novedoso y composiciones.
WO2008109785A2 (en) * 2007-03-06 2008-09-12 Rutgers, The State University Hiv reverse transcriptase compositions and methods
EP2142212A2 (en) * 2007-03-26 2010-01-13 International Aids Vaccine Initiative Method of elicting immune response with a modified mva viral hiv-1 vector
TW200911304A (en) 2007-05-24 2009-03-16 Glaxosmithkline Biolog Sa Lyophillised antigen composition
KR20100109555A (ko) * 2007-12-21 2010-10-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
CN102625714B (zh) * 2008-07-16 2015-08-19 贝勒研究院 基于将最大化的gag和nef靶向树突细胞的hiv疫苗
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
WO2010029562A1 (en) 2008-09-09 2010-03-18 Mukesh Harilal Shukla Bioactive composition for the treatment of the hiv/aids, method for manufacturing and using the same
SG177744A1 (en) 2009-07-24 2012-02-28 Immune Design Corp Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
CA2794558A1 (en) 2010-03-26 2011-09-29 Patricia Bourguignon Hiv vaccine
SI2569008T1 (sl) 2010-05-14 2020-02-28 Baxalta Incorporated Himere OSPA in njihova uporaba v cepivih
SG188624A1 (en) * 2010-09-27 2013-04-30 Glaxosmithkline Biolog Sa Vaccine
JP2012120506A (ja) * 2010-12-10 2012-06-28 Tosoh Corp Ａｍｖ逆転写酵素遺伝子、該遺伝子によりコードされるａｍｖ逆転写酵素及び該遺伝子を用いるａｍｖ逆転写酵素の製造方法
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
JP2013146235A (ja) * 2012-01-20 2013-08-01 Tosoh Corp トリ骨髄芽細胞腫ウイルス逆転写酵素の製造方法
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
NZ700340A (en) 2012-03-30 2017-02-24 Immune Design Corp Lentiviral vector particles having improved transduction efficiency for cells expressing dc- sign
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
US8323662B1 (en) 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
US9782473B2 (en) 2013-03-26 2017-10-10 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
TWI733652B (zh) 2014-07-11 2021-07-21 美商基利科學股份有限公司 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑
KR102014518B1 (ko) 2017-01-05 2019-08-26 서울대학교산학협력단 HIV 1의 p24 단백질을 발현하는 벡터가 도입된 재조합 마이코박테리움 스메그마티스 균주 및 이를 포함하는 백신
GB201812647D0 (en) 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
KR102922000B1 (ko) 2019-07-16 2026-02-05 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
BR112022009421A2 (pt) 2019-11-14 2022-10-25 Aelix Therapeutics S L Regimes de dosagem para vacinas
EP4126028A1 (en) 2020-03-27 2023-02-08 Svenska Vaccinfabriken Produktion AB Compositions and methods for treating and preventing coronaviruses
JP7693813B2 (ja) 2021-01-14 2025-06-17 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖワクチン及び使用方法
WO2023056284A1 (en) 2021-09-29 2023-04-06 Svenska Vaccinfabriken Produktion Ab Compositions and methods for treating and preventing coronavirus infection

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
DE3300234A1 (de) 1983-01-05 1984-07-05 Display-Design GmbH für moderne Verkaufsförderungsmittel und Raumaussstattung, 6233 Kelkheim Etagenturm zur warenausstellung
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
DK643188A (da) * 1987-11-24 1989-05-25 Smithkline Biolog Ekspression af hiv-proteiner i e.coli og s.cerevisiae
US5221610A (en) 1988-05-26 1993-06-22 Institut Pasteur Diagnostic method and composition for early detection of HIV infection
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
CA2085827C (en) 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
KR0172970B1 (ko) 1992-06-17 1999-02-01 김영길 Aids백신에 유용한 키메릭 단백 및 그의 제조방법
ATE188613T1 (de) 1992-06-25 2000-01-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
JP4028593B2 (ja) 1993-03-23 2007-12-26 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム ３−ｏ脱アシル化モノホスホリルリピドａ含有ワクチン組成物
EP0717752B1 (en) 1993-05-18 2004-11-24 Macfarlane Burnet Centre For Medical Research Limited Therapeutic compounds
KR100355470B1 (ko) 1993-11-17 2003-02-17 도이체 오엠 아르 쯔나이미텔 게엠바하 글루코사민이당류,그의제조방법,이를함유하는제약학적조성물,및그의용도
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
PT772619E (pt) 1994-07-15 2006-10-31 Univ Iowa Res Found Oligonucleotidos imunomoduladores
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
AU4992197A (en) 1996-10-11 1998-05-11 Regents Of The University Of California, The Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
AU734180B2 (en) 1997-08-29 2001-06-07 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
JP4637356B2 (ja) 1998-08-04 2011-02-23 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド 広い反応性の中和抗体応答を伴うｈｉｖ−１エンベロープタンパク質の発現およびキャクタライゼーション
CA2393861A1 (en) 1999-12-17 2001-06-21 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
PT1240186E (pt) * 1999-12-23 2010-03-25 Int Aids Vaccine Initiative Melhorias em respostas imunitárias ou relacionadas com respostas imunitárias ao hiv
US20020155127A1 (en) * 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
WO2002022080A2 (en) 2000-09-15 2002-03-21 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
CU23235A1 (es) * 2001-02-28 2007-09-26 Ct Ingenieria Genetica Biotech POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
WO2003046124A2 (en) 2001-11-21 2003-06-05 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
AU2002327338A1 (en) * 2001-07-25 2003-02-17 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
CN100392085C (zh) * 2001-09-20 2008-06-04 葛兰素集团有限公司 疫苗
US20030134404A1 (en) 2001-11-26 2003-07-17 Lochrie Michael A. Methods for producing stocks of recombinant AAV virions
US20030190308A1 (en) 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
ATE420658T1 (de) * 2002-03-19 2009-01-15 Powderject Res Ltd Imidazoquinolinamine als adjuvantien für hiv dna vakzine
DE60313163T2 (de) * 2002-06-11 2008-01-03 Glaxosmithkline Biologicals S.A. Immunogene zusammensetzungen
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US7501503B2 (en) * 2002-12-31 2009-03-10 Mcgill University Compositions and methods for inhibiting RNase H activity of retroid reverse transcriptase
WO2005030964A1 (en) 2003-09-24 2005-04-07 Oxxon Therapeutics Limited Hiv pharmaccines
US20050175627A1 (en) 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines

Also Published As

Publication number Publication date
CA2575898C (en) 2015-09-29
DK1773999T3 (da) 2010-01-18
ES2486669T3 (es) 2014-08-19
SG155206A1 (en) 2009-09-30
EP1773999B1 (en) 2009-09-23
JP2011234722A (ja) 2011-11-24
JP6007212B2 (ja) 2016-10-12
NZ552976A (en) 2010-01-29
EP2130921A2 (en) 2009-12-09
TW200621806A (en) 2006-07-01
KR20070041765A (ko) 2007-04-19
PE20060577A1 (es) 2006-08-07
MY145614A (en) 2012-03-15
GB0417494D0 (en) 2004-09-08
DE602005016810D1 (de) 2009-11-05
RU2441878C2 (ru) 2012-02-10
SI1773999T1 (sl) 2010-01-29
EP2130921A3 (en) 2010-03-03
IL180947A0 (en) 2007-07-04
ZA200700771B (en) 2009-04-29
IL207575A0 (en) 2011-07-31
PT1773999E (pt) 2009-12-16
EP2280073A3 (en) 2011-06-29
US20100184836A1 (en) 2010-07-22
NO20070988L (no) 2007-05-04
EP2280073A2 (en) 2011-02-02
ES2334044T3 (es) 2010-03-04
JP5629647B2 (ja) 2014-11-26
US7612173B2 (en) 2009-11-03
US20070243203A1 (en) 2007-10-18
MX2007001515A (es) 2007-09-07
PL1773999T3 (pl) 2010-02-26
MA28983B1 (fr) 2007-11-01
CN102633866B (zh) 2015-04-15
CN101035897B (zh) 2012-02-01
CN102633866A (zh) 2012-08-15
TWI365191B (en) 2012-06-01
BRPI0514108A (pt) 2008-05-27
AU2005268856B2 (en) 2012-05-24
KR101501495B1 (ko) 2015-03-11
EP1773999A2 (en) 2007-04-18
HRP20090678T1 (hr) 2010-01-31
EP2280073B1 (en) 2014-06-11
RU2007104088A (ru) 2008-09-10
HK1108168A1 (en) 2008-05-02
CY1109667T1 (el) 2014-08-13
WO2006013106A2 (en) 2006-02-09
ES2445453T3 (es) 2014-03-03
JP2014239687A (ja) 2014-12-25
EP2130921B1 (en) 2013-11-20
AU2005268856A1 (en) 2006-02-09
ATE443769T1 (de) 2009-10-15
JP2008507987A (ja) 2008-03-21
CN101035897A (zh) 2007-09-12
AR080216A2 (es) 2012-03-21
WO2006013106A3 (en) 2006-08-17
CA2575898A1 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
AR050102A1 (es) Polipeptidos de fusion de vih para la prevencion y /o tratamiento del sida
EA200001030A1 (ru) Получение капсул и таблеток быстрорастворяющегося эфавиренза с использованием супердезинтеграторов
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
MX9403380A (es) Inhibidores de proteasa de vih utiles para el tratamiento de sida.
CR6491A (es) Composiciones y metodos inmunogenicos de hiv
NO20070551L (no) Vaksinesammensetninger og fremgangsmater for behandling av koronavirus infeksjon.
AR036566A1 (es) Vacunas para vih 1
AR031520A1 (es) Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion
AR072302A1 (es) Pestivirus atenuados. composicion inmunogenica. metodo.
CO6290701A2 (es) Vacuna de vih que comprende una proteina de fusion y un agente estabilizador
JP2002533125A5 (es)
MXPA05005202A (es) Vacuna.
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
PE20060149A1 (es) Formulacion farmaceutica para tratar la infeccion por vih
TW200726479A (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
AP1674A (en) The genome of the HIV-1 inter-subtype (C/B') and use thereof.
EA200500533A1 (ru) Пептидные производные - ингибиторы слияния при вич-инфекции
JP2008539164A5 (es)
WO1990013281A3 (en) Method of suppressing hiv infection
DE60213874D1 (de) Verfahren zur herstellung von protease hemmenden zwischenprodukten
CA2306441A1 (fr) Peptides issus de gene env du virus de l'immunodeficience feline et leurs applications
PE20090163A1 (es) CONJUGADOS DE PEPTIDOS ANTIFUSOGENICOS Y POLIPEPTIDOS DERIVADOS DE LA CABEZA GLOBULAR DEL FACTOR DEL COMPLEMENTO C1q
WO2005027844A3 (en) Dna vaccine compositions and methods of use
ES2192433A1 (es) Produccion del antigeno vp60, o de un fragmento del mismo, del virus de la enfermedad hemorragica de los conejos en plantas y vacuna contra la enfermedad hemorragica virica de los conejos que comprende dicho antigeno.
WO2003089000A3 (fr) Composition anti-vih, comprenant un polyanion et un agent agissant sur gp120 de acon equivalent au cd4

Legal Events

Date Code Title Description
FG Grant, registration